neoadjuvant chemoradiation + SHR-1210

This is a combination therapy consisting of neoadjuvant chemoradiation and SHR-1210 (camrelizumab). Neoadjuvant chemoradiation refers to the use of chemotherapy and radiation therapy before the main treatment (usually surgery) to shrink tumors and improve surgical outcomes. It is commonly used in cancers such as rectal, esophageal, lung, and breast cancer[1][2][3][4][5][6]. SHR-1210 (camrelizumab) is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells. By blocking PD-1, it enhances immune system activity against cancer cells. Camrelizumab has been developed primarily for various solid tumors including non-small cell lung cancer and esophageal squamous cell carcinoma. The combination aims to maximize tumor reduction prior to surgery by both direct cytotoxic effects (chemoradiation) and immune-mediated anti-tumor activity (camrelizumab).

Brand names

camrelizumab

Other names

neoadjuvant chemoradiationcamrelizumabneoadjuvant chemoradiotherapy + camrelizumab